The long-acting GLP-1 receptor (GLP-1R) agonists exendin-4 (Ex-4) and liraglutide are approved therapeutics for the treatment of type 2 diabetes mellitus (T2DM) [8]. This evidence concerns the gene GLP1R and diabetes mellitus.